Synchronous Bilateral Breast Cancer With Discordant Receptor Status: Treating One Patient but Two Diseases
Abstract
The expression of hormone receptors (estrogen and progesterone) and human epidermal growth factor receptor-2 (HER2) has been used for both therapeutic and prognostic purposes in the management of breast cancer. The presence of a discordant receptor status complicates the approach to treatment in patients with synchronous bilateral breast cancer. We describe the case of a 45-year-old female with synchronous bilateral breast cancer with a triple-negative tumor and a contralateral HER2-positive tumor and discussed the impact of this on the approach to therapeutic management.
World J Oncol. 2023;14(3):224-229
doi: https://doi.org/10.14740/wjon1603